I am going to make an assumption and as we all kno

I am going to make an assumption and as we all know there are dangers in doing so. The assumption is that we are in the middle of a process in which the N-Assay is being finalized and the Faro's are nearing the completion of a critical stage of their testing and should be close to reporting on such. Added to this is the fact that NanoLogix has an agreement with a Singaporean partner that is well-positioned to market the packaging tech inside China to locations in absolute need of the product's special capacities and the ability to pay for and use it in volume. I am also going to assume that as we have seen in prior reports that marketing and sales are developing and we hope revenues expanding. BUT those revenues will only be positive in relation to raising the share price when they are closer to something dramatic. In other words, those of us holding the shares should not want to see financial information until a strategic point when that $$ level is at the point where it has the ability to "move the market" on share prices. Right now the trading volume is low because we are treading water and unwilling to sell at prices that are likely significantly lower than share prices will be when and if the sales of the close to emerging N-Assay and packaged petri dishes with long life under harsh conditions start on a steep upward curve. This doesn't even begin to deal with the possibility of a partnership with a significant medical supplies company (or a sale) although the N-Assay's potential makes those possibilities more probable.

So, I don't want to see financials until they are sufficient to drive the share price upward. Once they are then we can also see if there is momentum for upgrading the stock classification so that the shares are traded on a more significant market than at the present time.